Answers are grounded in this paper and cite their sources.
Replicative cellular senescence (CS) is characterized by a stable arrest of cell proliferation, typically triggered by progressive telomere shortening to a critical length, thereby initiating the senescence process in the absence of human telomerase reverse transcriptase (hTERT) activity. The accumulation of senescent cells has been implicated as a major driver of aging and age-related diseases. This study investigated whether pharmacological activation of telomerase using small-molecule compounds (AGS-499 and AGS-500) could modulate molecular, proliferative, and functional markers of senescence-associated stress in human dermal fibroblasts (HDFs). Early-passage (P.17-P.21) and late-passage HDFs (P.41–P.66) were treated with AGS compounds. Telomerase activity was quantified in soluble and DNA-bound protein fractions using the Telomere Repeat Amplification Protocol (TRAP). hTERT mRNA expression was assessed via Quantitative real-time polymerase chain reaction (qRT-PCR). hTERT protein levels were measured by Enzyme-linked immunosorbent assay (ELISA) in DNA-bound fractions. The functional impact on senescence-associated stress was measured through Senescence-Associated β-galactosidase (SA-β-gal) staining following a 14-day treatment regimen. Proliferative capacity was assessed by carboxyfluorescein succinimidyl ester (CFSE) dilution and flow cytometry, and the motility of individual late-passage cells was assessed by time-lapse confocal microscopy. Treatment with AGS-499 and AGS-500 significantly elevated telomerase activity in the DNA-bound fraction, with late-passage cells exhibiting up to a 2.3-fold increase relative to untreated controls and a 3.5-fold increase relative to Dimethyl sulfoxide (DMSO) treated cells, the latter partly reflecting a vehicle-associated reduction in telomerase activity. In the soluble fraction, significant increases were observed in early-passage cultures. AGS-499 induced a significant 2-fold increase in hTERT mRNA compared to untreated cells (8.5-fold compared to DMSO-treated cells). ELISA quantification confirmed that hTERT protein levels decline significantly with passage and that AGS-499 and AGS-500 significantly increased DNA-bound hTERT protein in late-passage cells by approximately 20% relative to vehicle controls. Long-term treatment led to a ~ 25% reduction in SA-β-gal-positive cells. In CFSE-labeled P.41 cultures, AGS-500 increased the fraction of cells in the lower-CFSE intervals after 8 days to 66.15%, compared with 43.13% in DMSO-treated cells, through a broad shift of the principal fluorescence distributions rather than expansion of a minor subpopulation. In P.66 cultures, AGS-499 increased the mean cumulative migration distance of individual cells from 32.18 ± 2.79 to 42.18 ± 1.92 ( p = 0.006), and AGS-500 produced a comparable increase 40.86 ± 3.93 μm ( p = 0.039). Targeted pharmacological activation of telomerase using AGS compounds partially attenuates several molecular, proliferative, and functional features of senescence-associated stress in human fibroblasts. These results support the view that senescence-associated stress retains a degree of pharmacological plasticity and highlight controlled telomerase activation as a potential strategy for attenuating age-associated cellular dysfunction, pending confirmation of the underlying telomere-dependent and telomere-independent mechanisms. Not applicable.
No takes yet. Share an insight, caveat, or question.
Yehuda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: